- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06441331
Fase I-forsøk for å bestemme dosen og evaluere PK av Lutetium Lu 177 Edotreotidterapi hos pediatriske deltakere med SSTR-positive svulster (KinLET)
En multisenter, åpen, intervensjonell fase I-forsøk for å bestemme dosen og evaluere farmakokinetikken (PK) og sikkerheten til Lutetium Lu 177 Edotreotid-målrettet radiofarmasøytisk terapi (RPT) som monoterapi eller etter standard omsorg (SoC) for behandling av somatostatin Reseptor-positive svulster i den pediatriske populasjonen (KinLET).
The purpose of the study is to determine the appropriate pediatric dosage and evaluate the pharmacokinetics (PK) and safety of Lutetium Lu 177 Edotreotide Targeted Radiopharmaceutical Therapy (RPT) as a monotherapy or following standard of care (SoC) in participants ≥2 to <18 years of age with somatostatin receptor (SSTR)-positive tumors.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
Determine the dose, pharmacokinetics and safety of Lutetium Lu 177 Edotreotide as monotherapy or following sequential standard of care in pediatric participants with recurrent, progressive or refractory NET, CNS, lymphoma and other solid tumors that express SSTRs by immunohistochemistry and demonstrate uptake by somatostatin receptor imaging. Lutetium Lu 177 Edotreotide will be given intravenously once every 8 weeks for a total of up to 6 doses over an average of 48 weeks in participants aged 2-18 years.
Studietype
Registrering (Antatt)
Fase
- Fase 1
Kontakter og plasseringer
Studiekontakt
- Navn: Serhii Melnyk, MD
- E-post: kinlet@itm-radiopharma.com
Studer Kontakt Backup
- Navn: Pia Zehkorn
- Telefonnummer: +4989 32989866000
- E-post: kinlet@itm-radiopharma.com
Studiesteder
-
-
California
-
Palo Alto, California, Forente stater, 94304
- Rekruttering
- Lucile Packard Children's Hospital at Stanford
-
Ta kontakt med:
- Raya Hamad Saab, Prof
- Telefonnummer: (650) 497-8953
- E-post: rsaab@stanford.edu
-
San Francisco, California, Forente stater, 94158
- Rekruttering
- UCSF Benioff Children's Hospital
-
Ta kontakt med:
- Kieuhoa T. Vo, MD
- Telefonnummer: 415-476-3831
- E-post: kieuhoa.vo@ucsf.edu
-
-
Ohio
-
Cincinnati, Ohio, Forente stater, 45229
- Rekruttering
- Cincinnati Children's Hospital Medical Center
-
Ta kontakt med:
- Brian K. Turpin, Do
- E-post: brian.turpin@cchmc.org
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forente stater, 19104-4319
- Rekruttering
- The Children's Hospital of Philadelphia (CHOP)
-
Ta kontakt med:
- Theodore W. Laetsch, MD
- E-post: laetscht@chop.edu
-
-
Texas
-
Houston, Texas, Forente stater, 77030
- Rekruttering
- University of Texas - MD Anderson Cancer Center
-
Ta kontakt med:
- David McCall, MD
- E-post: dmccall1@mdanderson.org
-
-
-
-
-
Marseille, Frankrike, 13005
- Rekruttering
- CHU de Marseille - Hôpital de la Timone
-
Ta kontakt med:
- Nicolas Andre, Prof
- E-post: nicolas.andre@ap-hm.fr
-
Villejuif, Frankrike, 94800
- Rekruttering
- Gustave Roussy Cancer Campus
-
Ta kontakt med:
- Charlotte Rigaud, Dr
- E-post: charlotte.rigaud@gustaveroussy.fr
-
-
-
-
-
Barcelona, Spania, 08035
- Rekruttering
- Hospital Universitario Vall d'Hebron - Oncología Médica
-
Ta kontakt med:
- Lucas Moreno, Dr.
- E-post: lucas.moreno@vallhebron.cat
-
Madrid, Spania, 28009
- Rekruttering
- Hospital General Universitario Gregorio Marañón
-
Ta kontakt med:
- Cristina Mata Fernandez, Dr
- Telefonnummer: +34 915290037
- E-post: cristina.mata@salud.madrid.org
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Key Inclusion Criteria:
- Participants aged ≥ 2 years and < 18 years
- Confirmed diagnosis somatostatin receptor-positive (SSTR-positive) disease.
- Tumor which is relapsed or is refractory to at least one line of previous therapy
- Positive SSTR protein expression confirmed by immunohistochemistry of a tumor histology sample
- Radioactivity uptake within the primary tumor or metastatic tumor sites measured by locally available SRIs ( 111In-based, 99mTc-based, or 68Ga-based SSTR single-photon emission computed tomography (SPECT)/ computed tomography (CT) or positron emission tomography (PET)/CT imaging, which is higher than the liver uptake)
- Participants must have recovered from the acute treatment related toxicities (defined as ≤ grade 1 if not defined in eligibility criteria, excluding alopecia, stable treated electrolyte abnormalities on replacement and stable treated hypothyroidism) of all prior treatment modality prior to entering this trial
- In case of sequential treatment followed by SoC or prior therapy, washout period applies before starting targeted RPT
Screening Consent Participant/legal guardian is willing to sign a screening consent. The screening consent is to be obtained according to institutional guidelines. Assent, when appropriate, will be obtained according to institutional guidelines.
Key Exclusion Criteria:
- Known hypersensitivity to Lutetium Lu 177 Edotreotide, DOTA/Edotreotide, or excipients
- Previous history of acute leukemia unless in remission for at least two years
- Extensive bone/bone marrow involvement as per Investigator's judgement unless peripheral blood stem cells (PBSC) are available at a minimum of 2.5x106 CD34+ cells/kg
- Patients who have received previous systemic targeted RPT
- Previous treatment with metaiodobenzyl guanidine (MIBG) if the predicted overall exposure is expected to exceed 2 Gy (gray) to the bone marrow or 23 Gy to the kidney.
- Previous treatment with external beam radiation therapy (EBRT) if the predicted overall exposure is expected to exceed more than 2 Gy to the bone marrow or 23 Gy to the kidney.
- Previous treatment with oncologic immune vaccine or CAR-T cell therapy
- Bulky disease in the CNS
- Presence of severe renal, hepatic, electrolyte, cardiovascular, or hematological dysfunction
- Participants who have received a live-attenuated vaccine up to four weeks prior to enrolment
- Pregnant or breastfeeding women.
- Other known malignancies.
- Serious non-malignant disease.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Three sequential age cohorts
Arms are based upon age at enrollment. The opening of the 2nd and 3rd cohort will depend on the recruitment of at least four participants with dosimetry and safety data for cycle 1, in the previous cohort.
|
lutetium Lu 177 edotreotide At least two cycles and a maximum of six cycles at eight-week (± 2 we-ek) intervals. Extrapolation from standard maximum adult dose of 100 Megabecquerel(MBq)/kg for a 75 kg adult for the first cohort. Dosing decision for the subsequent cohorts by Data Monitoring Committee (DMC), based on (at least) cycle 1 dosimetry and safety data from at least four participants of the preceding cohort. Route of administration: Intravenous (IV) infusion. Duration of treatment: 16-48 weeks
Andre navn:
The Amino-Acid Solution (AAS) to be used in this study will contain a mixture of lysine and arginine diluted in an electrolyte solution.
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Pediatric Dosage
Tidsramme: a. Dosimetry assessments will be performed at multiple timepoints in cycle 1, 2 and 4. - b. Minimum of eight weeks after the first administration of Lutetium Lu 177 edotreotide
|
Pediatric dosage based on:
|
a. Dosimetry assessments will be performed at multiple timepoints in cycle 1, 2 and 4. - b. Minimum of eight weeks after the first administration of Lutetium Lu 177 edotreotide
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Objective Response Rate
Tidsramme: At the end of Cycle 2 (each cycle is 28 days)
|
Assess preliminary anti-tumor activity by tumor type |
At the end of Cycle 2 (each cycle is 28 days)
|
|
PK and dosimetry
Tidsramme: Dosimetry assessments will be performed at multiple timepoints at Cycle 1, 2 and 4.
|
Lutetium Lu 177 edotreotide PK evaluation and tumor and target organ dosimetry |
Dosimetry assessments will be performed at multiple timepoints at Cycle 1, 2 and 4.
|
|
Rate of adverse events
Tidsramme: From treatment start until 33 days following the last dose of trial treatment or until the End of Last Treatment (EOLT) visit, whichever occurs later..
|
Safety evaluation of Lutetium Lu 177 edotreotide targeted RPT as monotherapy or following standard of care |
From treatment start until 33 days following the last dose of trial treatment or until the End of Last Treatment (EOLT) visit, whichever occurs later..
|
|
Overall Survival, Progression-Free Survival and Duration of Response
Tidsramme: Every 9 ± 3 weeks from enrollment until disease progression or for up to two years, whichever came first.
|
Additional preliminary efficacy evaluation of lutetium Lu 177 Edotreotide targeted RPT as monotherapy or following SoC |
Every 9 ± 3 weeks from enrollment until disease progression or for up to two years, whichever came first.
|
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Exploratory Endpoint: Quality of Life
Tidsramme: At enrollment, 18 days prior to cycles 2-6, four ± 3 weeks after targeted RPT.
|
Assess quality of life based on the adapted Quality of Life (QoL) scale (PedsQL TM 3.0 Cancer Module) |
At enrollment, 18 days prior to cycles 2-6, four ± 3 weeks after targeted RPT.
|
|
Exploratory Endpoint: Correlation between SSTR expression detected by immunohisto-chemistry and functional imaging
Tidsramme: No timeframe given.
|
Correlation of the expression level of SSTR immunohistochemistry in tumor biopsy or surgery samples and 111In-based, 99mTc-based, or 68Ga-based-based lesion uptake (regarding intensity/distribution) |
No timeframe given.
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: Roman Henkel, PhD, Director, Global Clinical Operations
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Sykdommer i nervesystemet
- Neoplasmer etter nettsted
- Neoplasmer
- Sykdommer i immunsystemet
- Neoplasmer etter histologisk type
- Neoplasmer, kjertel og epitel
- Lymfesykdommer
- Lymfoproliferative lidelser
- Immunproliferative lidelser
- Neoplasmer, Neuroepithelial
- Nevroektodermale svulster
- Neoplasmer, kjønnsceller og embryonale
- Neoplasmer, nervevev
- Neoplasmer i nervesystemet
- Sarkom
- Neoplasmer, bindevev og mykt vev
- Neuroektodermale svulster, primitive
- Neoplasmer, muskelvev
- Myosarkom
- Hemic og lymfatiske sykdommer
- Lymfom
- Nevroendokrine svulster
- Rhabdomyosarkom
- Neuroektodermale svulster, primitive, perifere
- Neoplasmer i sentralnervesystemet
- Gastro-enteropancreatic nevroendokrin tumor
- aminosyre, glukose og elektrolyttløsning
- 177LU-OCTREOTID, DOTA (0) -Tyr (3)-
Andre studie-ID-numre
- ITM-1191-01
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .